- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01532817
Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device
Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore™ Device, for the Relief of Acute Bronchoconstriction Due to Asthma
The purpose of this pilot study is to collect preliminary clinical data related to the safety and preliminary clinical benefits of non-invasive vagal nerve stimulation with the AlphaCore™ device for the relief of acute bronchoconstriction due to asthma.
Up to 30 subjects who meet all inclusion/exclusion criteria and consent to participate in the study may be enrolled at up to 5 investigational (study) sites. The study sites are clinic settings capable of treating any potential complications of bronchoconstriction, an acute exacerbation of asthma, and any emergencies associated with use of the investigational device.
Studienübersicht
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
California
-
San Diego, California, Vereinigte Staaten, 92123
- Allergy and Asthma
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55402
- CRI
-
-
Oklahoma
-
Tulsa, Oklahoma, Vereinigte Staaten, 74136
- Vital Prospects Clinical Research Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
INCLUSION CRITERIA: VISIT 1
- Is able to give written Informed Consent.
- Is between the ages of 18 and 65 years, male or female.
- Has a known history of mild to moderate asthma for at least 1 year as defined by GINA Guidelines.
- Is using a short acting beta-agonist for relief/rescue of asthma..
- At Visit 1, demonstrates current or historical (within 1 year) FEV1 reversibility of at least 12% (and 200ml) or greater within 15-30 minutes following administration of 4 inhalations of albuterol.
EXCLUSION CRITERIA: VISIT 1
- Has a history of lung cancer, chronic obstructive pulmonary disease (COPD), or other co-morbidity associated with irreversible narrowing of the airways.
- Has an abscess or other infection or lesion (including lymphadenopathy) at the AlphaCore™ treatment site.
- Has known or suspected moderate to severe atherosclerotic cardiovascular disease, carotid artery disease (e.g. bruits or history of TIA or CVA) or congestive heart failure (CHF).
- Has suspected or confirmed sepsis.
- Has a clinically significant irregular heart rate or rhythm.
- Has experienced recent clinically significant changes in blood pressure, has uncontrolled high blood pressure, or is presently receiving pressors to maintain blood pressure.
- Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
- Has a history of carotid endarterectomy or vascular neck surgery on the right side.
- Has been implanted with metal cervical spine hardware.
- Has a recent or repeated history of syncope.
- Has a recent or repeated history of seizures.
- Is pregnant or nursing, or of childbearing years and is unwilling to use an accepted form of birth control.
- Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.
- Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g., homeless, developmentally disabled, prisoner).
- Is a relative of or an employee of the Investigator or the clinical study site.
INCLUSION CRITERIA: VISIT 2
- No changes have occurred in the patient's health or status relative to the original inclusion and exclusion criteria and the patient continues to be eligible for participation in the study.
- Either (i) develops subjective symptoms of asthma (wheezing, shortness of breath, cough) for which the patient would normally self-medicate with a short acting beta agonist, and/or (ii) documents a drop of 20% from screening PEF scores as recorded in their patient diary.
- At Visit 2, FEV1 is the same or lower than the screening FEV1 previously measured at visit 1 or the PEF is the same or lower than the screening previously measured at Visit 1.
EXCLUSION CRITERIA: VISIT 2
- The patient self-administered a short-acting beta agonist within 6 hours prior to onset of asthma symptoms.
- The patient induced an asthma exacerbation by withholding their pre-treatment medication used for exercise-induced bronchoconstriction (EIB).
Has signs and symptoms of asthma instability at Visit 2:
- Lung Function: FEV1 < 50 % predicted.
- Signs and symptoms of extreme respiratory distress at rest.
- Rapid deterioration in respiratory status (sudden change in respiratory rate, decrease in oxygen saturation, change in consciousness, etc.).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: alphacore
noninvasive neurostimulation of the vagus nerve
|
A single 90 second stimulation to the vagus nerve on the right side of the neck
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Safety- Number of Participants With Adverse Events
Zeitfenster: From time subject signs the consent through the 1-week follow-up visit
|
Safety- number of participants with adverse events, including device-related, serious or unanticipated
|
From time subject signs the consent through the 1-week follow-up visit
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: John Erico, ElectroCore INC
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- BC-US-06
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Asthma
-
Vanderbilt University Medical CenterNoch keine RekrutierungAsthma bei Kindern | Asthmaanfall | Asthma akut | Akute Asthma-Exazerbation | Asthma; StatusVereinigte Staaten
-
Parc de Salut MarAktiv, nicht rekrutierendAsthma bei Kindern | Anhaltendes Asthma | Asthma-ExazerbationSpanien
-
University of California, San FranciscoAbgeschlossenAsthma bei Kindern | Asthmaanfall | Asthma akut | Asthma chronischVereinigte Staaten
-
SingHealth PolyclinicsNoch keine RekrutierungAsthma | Asthma bei Kindern | Asthmaanfall | Asthma akut | Asthma chronisch
-
Brunel UniversityKarolinska InstitutetUnbekanntBelastungsinduziertes AsthmaVereinigtes Königreich
-
Skane University HospitalSwedish Heart Lung FoundationAbgeschlossenAtemfunktionstests
-
Johann Wolfgang Goethe University HospitalAbgeschlossen
-
Universita di VeronaAbgeschlossen
-
Societa Italiana di PneumologiaSocietà Italiana di Allergologia, Asma e Immunologia ClinicaRekrutierungAsthma | Mittelschweres Asthma | Leichtes AsthmaItalien
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Karolinska Institutet; University of the Basque Country (UPV/EHU); Instituto de... und andere MitarbeiterAbgeschlossenPädiatrisches Asthma | Unkontrolliertes AsthmaSchweden, Deutschland, Niederlande, Slowenien, Spanien